Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes Mellitus

Table 3

Comparison of clinical background between the effective group and ineffective group in nonobese subjects with type 2 diabetes (BMI < 25 kg/m²).

Clinical parameter	Effective group	Ineffective group	value
Number	89	35
Gender (men/women); n (%)	56 (63)/33 (37)	18 (51)/17 (49)	N.S.
Age (year)	68.9 ± 9.4	69.0 ± 10.2	N.S.
BMI (kg/m^2)	22.1 ± 1.9	21.4 ± 2.6	N.S.
Duration of diabetes (year)	17.8 ± 9.9	15.2 ± 8.4	N.S.
Family history of diabetes (%)	66	44	N.S.
Baseline HbA1c (%) (mmol/mol)	7.7 ± 1.0	7.1 ± 0.7	0.0003
	61 ± 10.9	54 ± 7.7
Body weight change (kg)	0.5 ± 2.4	1.0 ± 2.7	N.S.
Total cholesterol (mg/dl)
Baseline	180 ± 32	173 ± 32	N.S.
Average over 1 year	175 ± 29	179 ± 31	N.S.
Triglyceride (mg/dl)
Baseline	109 ± 59	96 ± 44	N.S.
Average over 1 year	108 ± 48	108 ± 46	N.S.
HDL cholesterol (mg/dl)
Baseline	58 ± 15	56 ± 17	N.S.
Average over 1 year	57 ± 14	56 ± 16	N.S.
LDL cholesterol (mg/dl)
Baseline	95 ± 25	93 ± 21	N.S.
Average over 1 year	93 ± 20	95 ± 22	N.S.

BMI: body mass index; HDL: high-density lipoprotein; LDL: low-density lipoprotein; N.S.: not significant. Data are described as mean ± SD.